Recombinant DNA Advisory Committee - 2/10-11/92 
Dr. Mclvor stated that initially he was not in favor of merging the subcommittee with the 
parent committee. At the outset, human gene therapy/transfer protocols needed two 
reviews. However, recent protocols have required few revisions and several could have 
been approved with only one review necessary. Now he would vote in favor of this 
motion, although the RAC needs to be prepared to recommend deferrals of protocols. 
Dr. B. Murray read the changes to the original motion. In the introductory paragraphs, 
the phrase "that the Director should take" is deleted. Under number 1, the phrase under 
membership, "the membership of the RAC should be realigned so that it includes a greater 
expertise," will read "the membership of the RAC should emphasize expertise." Under 
number 2, the phrase "this realignment should be achieved by appointing to full 
membership in the RAC' will read "this should be achieved by recommending full 
membership in the RAC." Under number 4, the phrase "the HGTS should continue to 
operate as a subcommittee of the RAC" will read "the members of the HGTS should 
continue to contribute to the work of the RAC." Under number 4, the phrase "it should 
review our experience" will read "they should review our experience." Under number 4, 
the phrase "the subcommittee should also consider various types" will read "the members 
of the subcommittee should also consider various types." 
All the "transfers" in the motion will change to "transfer/therapy." Dr. Walters suggested a 
change under number 3 in the phrase "ORDA should also encourage IBCs to become 
more familiar" to read "ORDA should also encourage IRBs and IBCs to become more 
familiar." Dr. Post suggested deleting under number 3 the phrase "proposals pending at 
the March 30-31 meeting should be continued to be considered at that meeting." Dr. B. 
Murray said if this phrase is deleted, the Office of Recombinant DNA Activities (ORDA) 
can determine if there will be a March meeting depending on budget constraints. 
The motion, with amendments, was passed by a vote of 14 in favor, 0 opposed, and no 
abstentions. 
VIII. PROPOSED AMENDMENT TO APPENDICES B-I-B-l AND B-I-B-2 OF THE NIH 
GUIDELINES REGARDING THE BACTERIAL ORDER, ACTINOMYCETALES 
Review— Dr. Krogstad 
Dr. Krogstad reported that the RAC Working Group on Actinomycetales held a telephone 
conference call on November 13, 1991, to develop a list of pathogens. Other working 
group members included Drs. B. Murray, Fleming, and Schaechter. Originally, a list of 19 
organisms was developed. This list included both the proven pathogens identified by the 
Centers for Disease Control (CDC) and the suspected pathogens identified by the CDC 
that were also part of risk group 2 (Biosafety Level 2) in the German classification, 
[352] 
Recombinant DNA Research, Volume 15 
